Physician profile
Keith Bates
NPI 1255031050
$1,004.32
in general payments reported to CMS, 2019-2025
14 companies · $490 in 2025
The $490 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $238 · 2024: $277 · 2025: $490.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,004.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,004.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $266.12 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $189.12 | 2023-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $118.33 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Exact Sciences Corporation | $95.54 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novartis Pharmaceuticals Corporation | $93.87 | 2023-2024 | |
| Amgen INC. | $59.38 | 2024-2025 | Otezla, Repatha, Repatha |
| Merck Sharp & Dohme LLC | $35.84 | 2024 | Gardasil 9, Gardasil, Proquad |
| Glaxosmithkline, LLC. | $32.70 | 2023-2024 | Trelegy Ellipta |
| Dexcom, INC. | $27.41 | 2023 | Dexcom G6 Transmitter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.51 | 2025 | Caplyta |
| Pfizer INC. | $19.33 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.34 | 2023 | Cuvitru |
| Bayer Healthcare Pharmaceuticals INC. | $14.95 | 2025 | |
| Phathom Pharmaceuticals, INC. | $11.88 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Bates listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.